Pharmaceutical companies holding medicine patents in Brazil will be pleased to hear that the country’s National Congress has backed President Jair Bolsonaro’s decision to veto parts of a law that would have required firms to provide extensive information on products subject to a compulsory license.
Brazil Waters Down Compulsory Licensing Law
Companies in Brazil will not have to provide know-how and other detailed information on patents that are subject to compulsory licenses, although other provisions of a law passed last year to ease the compulsory licensing process remain in place.
More from Legal & IP
More from Pink Sheet
Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry
• By
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
• By
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
• By
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.